Rheumatoid ArthritisPhase 3NCT01232569
A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
A Phase 3 study testing Tocilizumab 162 mg in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 141 sites in 22 countries.
Trial summary
This randomized, parallel-group, placebo-controlled, multicenter study will evaluate the reduction in disease activity and the safety of tocilizumab (RoActemra/Actemra) in combination with traditional disease-modifying anti-rheumatic drugs (DMARDs) in patients with active, moderate to severe rheumatoid arthritis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Rheumatoid Arthritis
- What is being tested?
- Tocilizumab 162 mg
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 656 participants
- Where
- 141 sitesin 22 countries
- Study dates
- Mar 2011to Nov 2013
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patients, ≥ years of age.
- Moderate to severe rheumatoid arthritis of ≥ 6 months duration.
- Receiving treatment on an outpatient basis.
- Swollen joint count (SJC) ≥ 6 (66 joint count) and tender joint count (TJC)≥ 8 (68 joint count) at screening and study start.
- On a stable dose of disease-modifying anti-rheumatic drugs for at least 8 weeks prior to study start.
Who cannot join
- Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization.
- Rheumatic autoimmune disease other than rheumatoid arthritis, Secondary Sjögren's Syndrome with rheumatoid arthritis is allowed.
- Functional class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in Rheumatoid Arthritis.
- Diagnosis of juvenile idiopathic arthritis or juvenile rheumatoid arthritis and/or rheumatoid arthritis before the age of 16 years.
- Prior history of or current inflammatory joint disease other than rheumatoid arthritis.
- History of malignancy, active or recurrent infections, positive to hepatitis B surface antigen or hepatitis C antibody, active tuberculosis, serious allergy to biologics, or a history of diverticular disease or other symptomatic GI conditions that might predispose to perforations.
- Other inclusion and exclusion criteria applied to the study.
Trial locations and contacts
141 sites in 22 countries.
141 sites in 22 countries
United States44 sites
Study site
Allentown, Pennsylvania, 18103
Study site
Belmont, North Carolina, 28012
Study site
Bethlehem, Pennsylvania, 18015
Study site
Boca Raton, Florida, 33486
Study site
Brooklyn, New York, 11201
Study site
Charlotte, North Carolina, 28204
Study site
Charlotte, North Carolina, 28207
Study site
Charlotte, North Carolina, 28211
Study site
Crofton, Maryland, 21114
Study site
Dallas, Texas, 75246
Study site
Duncansville, Pennsylvania, 16635
Study site
Flowood, Mississippi, 39232
Study site
Fort Worth, Texas, 76107
Study site
Fullerton, California, 92835
Study site
Gainesville, Georgia, 30501
Study site
Hagerstown, Maryland, 21740
Study site
Houston, Texas, 77034
Study site
Houston, Texas, 77459
Study site
Idaho Falls, Idaho, 83404
Study site
Jackson, Mississippi, 39202
Study site
Jupiter, Florida, 33458
Study site
Lincoln, Nebraska, 68516
Study site
Memphis, Tennessee, 38104
Study site
Meridan, Idaho, 83642
Study site
Oklahoma City, Oklahoma, 73104
Study site
Ormond Beach, Florida, 32174
Study site
Peoria, Arizona, 85381
Study site
San Antonio, Texas, 78232
Study site
San Diego, California, 92108
Study site
San Leandro, California, 94578
Study site
Sarasota, Florida, 34292
Study site
Scottsdale, Arizona, 85258
Study site
Springfield, Illinois, 62704
Study site
St Louis, Missouri, 63128
Study site
St Louis, Missouri, 63141
Study site
Tacoma, Washington, 98405
Study site
Trumbull, Connecticut, 06611
Study site
Tucson, Arizona, 85723
Study site
Tucson, Arizona, 85724
Study site
Vernon Hills, Illinois, 60061
Study site
West Hills, California, 91307
Study site
Wexford, Pennsylvania, 15090
Study site
Wheaton, Maryland, 20902
Study site
Wyomissing, Pennsylvania, 19610
Brazil13 sites
Study site
Curitiba, 80060-240
Study site
Goiânia, 74043-011
Study site
Juiz de Fora, 36010-570
Study site
Porto Alegre, 90610-000
Study site
Porto Alegre, 91350-200
Study site
Rio de Janeiro, 22271-100
Study site
Salvador, 40050-410
Study site
São Paulo, 04026-000
Study site
São Paulo, 04266-010
Study site
São Paulo, 05437-010
Study site
São Paulo, 1244030
Study site
São Paulo, 5403900
Study site
Vitória, 29055-450
Russia12 sites
Study site
Kemerovo, 650099
Study site
Moscow, 115522
Study site
Moscow, 117049
Study site
Moscow, 129327
Study site
Novosibirsk, 630099
Study site
Petrozavodsk, 185019
Study site
Ryazan, 390026
Study site
Saint Petersburg, 190068
Study site
Saint Petersburg, 197022
Study site
Saint Petersburg, 197341
Study site
Ufa, 450005
Study site
Voronezh, 394066
Mexico11 sites
Study site
Chihuahua City, 31000
Study site
Culiacán, 80000
Study site
Guadalajara, 44158
Study site
León, 37320
Study site
Mérida, 97000
Study site
Mexicali, 21100
Study site
México, 44620
Study site
Morelia, 58070
Study site
Obregón, 85000
Study site
Querétaro, 76000
Study site
Querétaro, 76178
Israel7 sites
Study site
Ashkelon, 78306
Study site
Beersheba, 84101
Study site
Haifa, 31048
Study site
Haifa, 31096
Study site
Ramat Gan, 52621
Study site
Rishon LeZiyyon
Study site
Tel Aviv, 64239
Poland7 sites
Study site
Bytom, 41902
Study site
Działdowo, 13-200
Study site
Elblag, 82-300
Study site
Kościan, 64-000
Study site
Krakow, 31-121
Study site
Torun, 87-100
Study site
Warsaw, 02-653
Canada6 sites
Study site
Calgary, Alberta, T2N 2T9
Study site
London, Ontario, N6A 4V2
Study site
Ottawa, Ontario, K1H 1A2
Study site
Pointe-Claire, Quebec, H9R 3J1
Study site
Winnipeg, Manitoba, R3A 1M3
Study site
Winnipeg, Manitoba, R3N 0K6
Bulgaria5 sites
Study site
Plovdiv, 4002
Study site
Plovdiv, 4003
Study site
Sofia, 1612
Study site
Sofia, 2233
Study site
Varna, 9010
Switzerland4 sites
Study site
Fribourg, 1708
Study site
Geneva, 1211
Study site
Lausanne, 1011
Study site
Zurich, 8063
Argentina3 sites
Study site
Buenos Aires, C1015ABO
Study site
Córdoba, 5000
Study site
San Miguel de Tucumán, 4000
Colombia3 sites
Study site
Bogotá
Study site
Chia-cundinamarca
Study site
Medellín
Greece3 sites
Study site
Athens, 11527
Study site
Athens, 15121
Study site
Thessaloniki, 54636
Guatemala3 sites
Study site
Guatemala City, 01010
Study site
Guatemala City, 01013
Study site
Guatemala City, 01015
Malaysia3 sites
Study site
Batu Caves, 68100
Study site
Kota Kinabalu, 88586
Study site
Kuala Lumpur, 50603
Philippines3 sites
Study site
Cebu, 6000
Study site
Davao City, 8006
Study site
Manila, 1780
South Africa3 sites
Study site
Durban, 4013
Study site
Pinelands, 7405
Study site
Pretoria, 0002
Spain3 sites
Study site
A Coruña, 15006
Study site
Oviedo, 33006
Study site
Seville, 41009
About this study
Official title: A Randomized, Double-blind, Parallel Group Study of Safety and the Effect on Clinical Outcome of Tocilizumab Subcutaneous (sc) Versus Placebo sc in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients With Moderate to Severe Active Rheumatoid Arthritis
This randomized, parallel-group, placebo-controlled, multicenter study will evaluate the reduction in disease activity and the safety of tocilizumab (RoActemra/Actemra) in combination with traditional disease-modifying anti-rheumatic drugs (DMARDs) in patients with active, moderate to severe rheumatoid arthritis. In the double-blind part of the study, patients will be randomized to receive either 162 mg tocilizumab or placebo subcutaneously every 2 weeks for 24 weeks using a pre-filled syringe. In the open-label part of the study, patients will be randomized to receive 162 mg tocilizumab subcutaneously every 2 weeks from Week 24 to Week 96 using a pre-filled syringe or an auto-injector.
- Conditions
- Rheumatoid Arthritis
- Being tested
- Tocilizumab 162 mg, Placebo
- Medical subject headings
- Arthritis, Rheumatoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tocilizumab 162 mgDrug
Also called RoActemra, Actemra
Tocilizumab will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
PlaceboDrug
Placebo will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
| Study group | Role | What they receive |
|---|---|---|
| Tocilizumab 162 mg sc | Experimental | Patients will receive tocilizumab 162 mg subcutaneously (sc) every 2 weeks for 24 weeks. Receives: Drug: Tocilizumab 162 mg |
| Placebo sc | Placebo comparator | Patients will receive placebo subcutaneously (sc) every 2 weeks for 24 weeks. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24
A patient had an ACR20 response if there was at least a 20% improvement, ie, reduction from baseline, in tender and swollen joint counts (28 assessed joints) and in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, left end=no disease activity [symptom-free and no arthritis symptoms], right end=maximum disease activity; patient assessment of pain in previous 24 hours on a VAS (left end=no pain and right end=unbearable pain); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and acute-phase reactant (either C-reactive protein or erythrocyte sedimentation rate).
Measured: Baseline to Week 24
Secondary outcomes (16)
Percentage of Patients With ACR50 and ACR70 Responses at Week 24
A patient had an ACR50 response if there was at least a 50% improvement in the ACR scores. A patient had an ACR70 response if there was at least a 70% improvement in the ACR scores.
Measured: Baseline to Week 24
Time to Onset of ACR20, ACR50, and ACR70 Responses
Time to first ACR response was calculated as the number of days between the date of the first ACR response minus the date of the first dose of study drug. Median days are reported.
Measured: Baseline to Week 24
Change From Baseline in Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 24
Joints (28 joints) will be assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation on physical examination.
Measured: Baseline to Week 24
Change From Baseline in C-reactive Protein at Week 24
Measured: Baseline to Week 24
Change From Baseline in Erythrocyte Sedimentation Rate at Week 24
Measured: Baseline to Week 24
Change From Baseline in the Patient's and the Physician's Global Assessment of Disease Activity Visual Analog (VAS) Score
Patients and physicians assessed the patient's disease activity in the previous 24 hours on a 100 mm visual analog scale, where the extreme left end of the line represented "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end represented "maximum disease activity". Scores ranged from 0 to 100 with a higher score indicating more disease activity. A negative change score indicated less disease activity.
Measured: Baseline to Week 24
Change From Baseline in the Patient's Pain Visual Analog Score
Patients assessed their pain in the previous 24 hours on a visual analog scale, where the extreme left end of the line represented "no pain" and the extreme right end represented "unbearable pain". Scores ranged from 0 to 100 with a higher score indicating more pain. A negative change score indicated less pain.
Measured: Baseline to Week 24
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24
The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Patients completed the questionnaire by answering the 20 questions on a scale of 0 (without difficulty) to 3 (unable to do). The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.
Measured: Baseline to Week 24
Percentage of Patients With an Improvement of ≥ 0.3 Units From Baseline in the HAQ-DI Score at Week 24
The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Patients completed the questionnaire by answering the 20 questions on a scale of 0 (without difficulty) to 3 (unable to do). The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.
Measured: Baseline to Week 24
Change From Baseline in Disease Activity Score 28 (DAS28) at Week 24
The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity [symptom-free and no arthritis symptoms], right end = maximum disease activity [maximum arthritis disease activity]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A negative change score indicates improvement.
Measured: Baseline to Week 24
Percentage of Patients With a DAS28 Score ≤ 3.2 (DAS28 Low Disease Activity) at Week 24
The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity [symptom-free and no arthritis symptoms], right end = maximum disease activity [maximum arthritis disease activity]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A negative change score indicates improvement.
Measured: Baseline to Week 24
Percentage of Patients With a DAS28 Score < 2.6 (DAS28 Remission) at Week 24
The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity [symptom-free and no arthritis symptoms], right end = maximum disease activity [maximum arthritis disease activity]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A negative change score indicates improvement.
Measured: Week 24
Percentage of Patients With Good, Moderate, or no European League Against Rheumatism (EULAR) Responses at Week 24
Change of the Disease Activity Score 28 score from baseline was used to determine EULAR responses of good, moderate, or no response. For a post-baseline score ≤ 3.2, a change from baseline of < -1.2 was a good response, < -0.6 to ≥ -1.2 was a moderate response, and ≥ -0.6 was no response. For a post-baseline score > 3.2 to ≤ 5.1, a change from baseline of < -0.6 was a moderate response and ≥ -0.6 was no response. For a post-baseline score > 5.1, a change from baseline < -1.2 was a moderate response and ≥ -1.2 was no response. A good response could not be achieved for post-baseline scores > 3.2.
Measured: Baseline to Week 24
Change From Baseline in the Van Der Heijde Modified Sharp Radiographic Score at Week 24
The degree of joint damage was assessed using the van der Heijde modified total Sharp score (mTSS). The methodology quantifies the extent of bone erosions for 44 joints and joint space narrowing (JSN) for 42 joints, with higher scores representing greater damage. The independent read of X-ray images was performed by 2 primary readers. In case of discrepancy between the 2 primary readers, an adjudicator was involved. The mTSS can range from 0 to 448 with a higher score indicating more joint damage. A negative change score indicates improvement.
Measured: Baseline to Week 24
Change From Baseline in the Physical and Mental Component Scores of the Short Form 36 (SF-36) Health Survey at Week 24
The SF-36 Health Survey uses patient-reported symptoms on 8 subscales to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100 with a higher score indicating better HRQoL. A positive change score indicates an improvement in HRQoL.
Measured: Baseline to Week 24
Change From Baseline in Hemoglobin at Week 24
Measured: Baseline to Week 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Nov 2010 (estimated)
- Study startMar 2011
- Primary completionMay 2012
- Study completionNov 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Rheumatoid ArthritisStudies of the same condition, open and under way.
- More trials run by Hoffmann-La RocheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 656 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01232569
- Sponsor's protocol ID
- NA25220
- Other IDs
- 2010-019912-18
- Status last verified
- Jul 2015
- First submitted
- 1 Nov 2010
- Last updated
- 29 Jul 2015
- Results posted
- Yes, on ClinicalTrials.gov
Publications
Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, Merrill JT, Rowell L, Nasmyth-Miller C, Bao M, Wright S, Pope JE. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Nov;66(11):1653-61. doi: 10.1002/acr.22384.
PubMed 24942540
Study at a glance
From the registry record, last updated by the sponsor on 29 Jul 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-blind, Parallel Group Study of Safety and the Effect on Clinical Outcome of Tocilizumab Subcutaneous (sc) Versus Placebo sc in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients With Moderate to Severe Active Rheumatoid Arthritis
- ClinicalTrials.gov ID
- NCT01232569
- Acronym / sponsor ID
- NA25220
- Conditions
- Rheumatoid Arthritis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 656 participants (actual)
- Lead sponsor
- Hoffmann-La RocheIndustry (pharma, biotech, devices)
- Study start
- Mar 2011
- Primary completion
- May 2012 (actual)
- Study completion
- Nov 2013 (actual)
- First posted
- 2 Nov 2010 (estimated)
- Results
- Posted 23 Oct 2013
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized, parallel-group, placebo-controlled, multicenter study will evaluate the reduction in disease activity and the safety of tocilizumab (RoActemra/Actemra) in combination with traditional disease-modifying anti-rheumatic drugs (DMARDs) in patients with active, moderate to severe rheumatoid arthritis. In the double-blind part of the study, patients will be randomized to receive either 162 mg tocilizumab or placebo subcutaneously every 2 weeks for 24 weeks using a pre-filled syringe. In the open-label part of the study, patients will be randomized to receive 162 mg tocilizumab subcutaneously every 2 weeks from Week 24 to Week 96 using a pre-filled syringe or an auto-injector.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Tocilizumab 162 mg sc | Experimental | Drug: Tocilizumab 162 mgPatients will receive tocilizumab 162 mg subcutaneously (sc) every 2 weeks for 24 weeks. |
| Placebo sc | Placebo comparator | Drug: PlaceboPatients will receive placebo subcutaneously (sc) every 2 weeks for 24 weeks. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Adult patients, ≥ years of age.
- Moderate to severe rheumatoid arthritis of ≥ 6 months duration.
- Receiving treatment on an outpatient basis.
- Swollen joint count (SJC) ≥ 6 (66 joint count) and tender joint count (TJC)≥ 8 (68 joint count) at screening and study start.
- On a stable dose of disease-modifying anti-rheumatic drugs for at least 8 weeks prior to study start.
Key exclusion criteria (7 listed)
- Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization.
- Rheumatic autoimmune disease other than rheumatoid arthritis, Secondary Sjögren's Syndrome with rheumatoid arthritis is allowed.
- Functional class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in Rheumatoid Arthritis.
- Diagnosis of juvenile idiopathic arthritis or juvenile rheumatoid arthritis and/or rheumatoid arthritis before the age of 16 years.
- Prior history of or current inflammatory joint disease other than rheumatoid arthritis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tocilizumab 162 mgAlso: RoActemra, ActemraTocilizumab will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection. | Drug | Tocilizumab 162 mg sc |
| PlaceboPlacebo will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection. | Drug | Placebo sc |
Primary outcome
Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24
Time frame: Baseline to Week 24
A patient had an ACR20 response if there was at least a 20% improvement, ie, reduction from baseline, in tender and swollen joint counts (28 assessed joints) and in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, left end=no disease activity [symptom-free and no arthritis symptoms], right end=maximum disease activity; patient assessment of pain in previous 24 hours on a VAS (left end=no pain and right end=unbearable pain); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and acute-phase reactant (either C-reactive protein or erythrocyte sedimentation rate).
16 secondary outcomes
Percentage of Patients With ACR50 and ACR70 Responses at Week 24
Time frame: Baseline to Week 24
Time to Onset of ACR20, ACR50, and ACR70 Responses
Time frame: Baseline to Week 24
Change From Baseline in Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 24
Time frame: Baseline to Week 24
Change From Baseline in C-reactive Protein at Week 24
Time frame: Baseline to Week 24
Change From Baseline in Erythrocyte Sedimentation Rate at Week 24
Time frame: Baseline to Week 24
Change From Baseline in the Patient's and the Physician's Global Assessment of Disease Activity Visual Analog (VAS) Score
Time frame: Baseline to Week 24
Change From Baseline in the Patient's Pain Visual Analog Score
Time frame: Baseline to Week 24
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24
Time frame: Baseline to Week 24
Percentage of Patients With an Improvement of ≥ 0.3 Units From Baseline in the HAQ-DI Score at Week 24
Time frame: Baseline to Week 24
Change From Baseline in Disease Activity Score 28 (DAS28) at Week 24
Time frame: Baseline to Week 24
Percentage of Patients With a DAS28 Score ≤ 3.2 (DAS28 Low Disease Activity) at Week 24
Time frame: Baseline to Week 24
Percentage of Patients With a DAS28 Score < 2.6 (DAS28 Remission) at Week 24
Time frame: Week 24
Percentage of Patients With Good, Moderate, or no European League Against Rheumatism (EULAR) Responses at Week 24
Time frame: Baseline to Week 24
Change From Baseline in the Van Der Heijde Modified Sharp Radiographic Score at Week 24
Time frame: Baseline to Week 24
Change From Baseline in the Physical and Mental Component Scores of the Short Form 36 (SF-36) Health Survey at Week 24
Time frame: Baseline to Week 24
Change From Baseline in Hemoglobin at Week 24
Time frame: Baseline to Week 24
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jul 2015.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 24942540Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, Merrill JT, Rowell L, Nasmyth-Miller C, Bao M, Wright S, Pope JE. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Nov;66(11):1653-61. doi: 10.1002/acr.22384.
Related trials for Rheumatoid Arthritis
RecruitingPhase 2
Study of PTC844 in Participants With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Not yet recruitingPhase 1
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis and Systemic Lupus Erythematosus
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Hoffmann-La Roche
141 sites in 22 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Tocilizumab 162 mg in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 141 sites in 22 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Jul 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 141 sites in United States, Brazil, Russia, Mexico, Israel and 17 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 23 Oct 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24 (time frame: Baseline to Week 24). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01232569, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jul 2015.